Icecure Medical Ltd Ord (ICCM) Stock Price, Quote & News

Company Profile

IceCure Medical Ltd, a commercial stage medical device company, researches, develops, and markets cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers ProSense system, a single probe system for the treatment of malignant breast tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic...

Industry: Medical Devices

Sector: Healthcare

Phone: 972 4 623 0333

Fax: 972 4 623 0222

Website: www.icecure-medical.com

Address:

7 Ha’Eshel Street, PO Box 3163, Caesarea, Israel

Lyn30 Feb. 12 at 9:39 PM

$ICCM They r playing with this stock like all israeliiii stock. Even Chinese stock give chances many times to make money . But israeliiii one chance one shot . May be I missed that . Still not leaving but very disappointed put money here. My position here is big , whoever cover from my position if I do SL at any point may be will make huge 😂. My loss ur gain.

1 · Reply

BillionerOfKing Feb. 12 at 5:59 PM

$ICCM Current Stock Price: $0.60

0 · Reply

justme_DC Feb. 11 at 8:48 PM

$ICCM I like ICCM for what they do and their potential. BUT....if 1 particular hospital in St. Louis buying one of their set-ups is the best or only PR / news they have...we are in trouble and RS on the horizen is a fairly high likelihood.

2 · Reply

MahiMe Feb. 11 at 2:17 PM

$ICCM IceCure Medical" or the "Company"), a developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the most recent purchase and installation of the ProSense® system in the U.S. at St. Louis, Missouri based Shero Imaging, the first clinic in the state of Missouri to offer breast cancer cryoablation with ProSense®

0 · Reply

Planetpaprika Feb. 11 at 1:36 PM

$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/206/icecure-announces-shero-imaging-is-first-to-offer-breast-cancer-cryoablation-procedures-in-missouri-with-prosense

1 · Reply

Logan93 Feb. 9 at 9:55 PM

$ICCM Yet here we are three months later..

0 · Reply

Logan93 Feb. 9 at 9:52 PM

$ICCM key execs leaving doesn’t paint a rosy picture. In the few years I’ve followed it, it’s gone nowhere. Glad I got out a while back.

0 · Reply

ShadowView Feb. 9 at 2:23 PM

$ICCM Chinese consulting or IT services; faces economic and geopolitical headwinds.

0 · Reply

grandpa_dirt Feb. 6 at 4:33 PM

$ICCM While I'm extremely disappointed with the stock price, I feel like the company's management is following Israeli Companies Law and are working in the best interest of the organization. They have a product that took years of expensive development and testing, has a growing portfolio of patents and are gaining regulatory approvals in the most populous countries around the world. They release pressers a few times a month, and they are engaging in medical expos and forums. Their sales are increasing and if you look into the company heads compensation, they are not being greedy with ridiculous salaries. Med tech companies of this size die out all the time. Hurting long term investors in the short term thru dilution and reverse splits is preferable to outright bankruptcy, especially when they have a functioning product in an expanding field. To those raging at management, I would legitimately like to know what they should be doing different?

2 · Reply

Joe_088 Feb. 6 at 3:20 PM

$ICCM stop dilute fck stock !bad managment

0 · Reply

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense®

Feb 10, 2026, 4:00 PM EST - 3 days ago

NYSE Group Consolidated Short Interest Report

Feb 9, 2026, 4:30 PM EST - 4 days ago

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

Jan 28, 2026, 8:30 AM EST - 16 days ago

IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer

Jan 12, 2026, 8:30 AM EST - 4 weeks ago

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales

Dec 17, 2025, 8:30 AM EST - 2 months ago

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer

Dec 10, 2025, 8:30 AM EST - 2 months ago

IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

Dec 5, 2025, 8:30 AM EST - 2 months ago

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

Nov 19, 2025, 12:53 PM EST - 3 months ago

IceCure Medical Ltd (ICCM) Q3 2025 Earnings Call Transcript

Nov 19, 2025, 8:54 AM EST - 3 months ago

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

Nov 18, 2025, 8:30 AM EST - 3 months ago

IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

Nov 14, 2025, 4:30 PM EST - 3 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

Nov 12, 2025, 8:30 AM EST - 3 months ago

IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025

Nov 10, 2025, 8:30 AM EST - 3 months ago

IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction

Nov 3, 2025, 8:30 AM EST - 3 months ago

IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival

Oct 13, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances

Oct 9, 2025, 8:30 AM EDT - 4 months ago

IceCure Medical to Attend the 2025 Maxim Growth Summit

Oct 6, 2025, 11:25 AM EDT - 4 months ago

IceCure Medical Ltd - Special Call

Oct 3, 2025, 12:28 PM EDT - 4 months ago

IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care

Oct 3, 2025, 12:19 PM EDT - 4 months ago

IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above

Sep 30, 2025, 8:30 AM EDT - 4 months ago

IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented

Sep 22, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented

Sep 18, 2025, 8:30 AM EDT - 5 months ago

IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes

Sep 15, 2025, 8:30 AM EDT - 5 months ago

IceCure Receives Regulatory Approval in Israel for its Next-Generation XSense™ Cryoablation System for Breast Cancer and Other Indications

Sep 8, 2025, 8:30 AM EDT - 5 months ago

Two New Publications from the Independent THERMAC Trial Featuring IceCure's ProSense® in Breast Cancer Finds 95% of Patients Satisfied with Thermal Ablation; ProSense® Cryoablation Achieves Highest Complete Ablation Rate

Sep 4, 2025, 8:30 AM EDT - 5 months ago

IceCure's ProSense® Substantially Reduces Abdominal Wall Endometriosis Pain with High Procedural Efficacy

Aug 13, 2025, 1:08 PM EDT - 6 months ago

IceCure Medical Ltd (ICCM) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 8:30 AM EDT - 6 months ago

IceCure Reports Financial & Operational Results for the First Half of 2025

Aug 6, 2025, 8:30 AM EDT - 6 months ago

IceCure to Report First Half 2025 Financial and Operating Results on August 13, 2025

Jul 29, 2025, 9:00 AM EDT - 7 months ago

IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million

Jul 25, 2025, 9:00 AM EDT - 7 months ago

IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation

Jul 24, 2025, 9:00 AM EDT - 7 months ago

IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period

Jul 10, 2025, 8:00 AM EDT - 7 months ago

IceCure Announces Commencement of Rights Offering

Jul 3, 2025, 8:30 AM EDT - 8 months ago

IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025

Jun 25, 2025, 9:23 AM EDT - 8 months ago

IceCure Announces Record Date for Rights Offering for Up to $10 Million

Jun 9, 2025, 8:30 AM EDT - 8 months ago

IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes

May 28, 2025, 4:26 PM EDT - 9 months ago

IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript

May 28, 2025, 8:30 AM EDT - 9 months ago

IceCure Medical Reports First Quarter 2025 Financial Results

May 21, 2025, 8:30 AM EDT - 9 months ago

IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025

May 6, 2025, 8:30 AM EDT - 10 months ago

IceCure Receives High Level of Interest from Breast Surgeons at ASBrS 2025 Annual Meeting Following Recent Positive FDA Development on ProSense® Cryoablation

Apr 30, 2025, 8:30 AM EDT - 10 months ago

IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer

Apr 28, 2025, 8:30 AM EDT - 10 months ago

IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium

Apr 22, 2025, 8:30 AM EDT - 10 months ago

IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation

Mar 27, 2025, 1:45 PM EDT - 11 months ago

IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America

Mar 24, 2025, 8:30 AM EDT - 11 months ago

IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate

Mar 21, 2025, 8:30 AM EDT - 11 months ago

IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025

Mar 20, 2025, 8:30 AM EDT - 11 months ago

IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer

Mar 18, 2025, 8:30 AM EDT - 11 months ago

IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference

Mar 17, 2025, 8:30 AM EDT - 11 months ago

IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology

Lyn30 Feb. 12 at 9:39 PM

1 · Reply

BillionerOfKing Feb. 12 at 5:59 PM

$ICCM Current Stock Price: $0.60

0 · Reply

justme_DC Feb. 11 at 8:48 PM

2 · Reply

MahiMe Feb. 11 at 2:17 PM

0 · Reply

Planetpaprika Feb. 11 at 1:36 PM

$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/206/icecure-announces-shero-imaging-is-first-to-offer-breast-cancer-cryoablation-procedures-in-missouri-with-prosense

1 · Reply

Logan93 Feb. 9 at 9:55 PM

$ICCM Yet here we are three months later..

0 · Reply

Logan93 Feb. 9 at 9:52 PM

$ICCM key execs leaving doesn’t paint a rosy picture. In the few years I’ve followed it, it’s gone nowhere. Glad I got out a while back.

0 · Reply

ShadowView Feb. 9 at 2:23 PM

$ICCM Chinese consulting or IT services; faces economic and geopolitical headwinds.

0 · Reply

grandpa_dirt Feb. 6 at 4:33 PM

2 · Reply

Joe_088 Feb. 6 at 3:20 PM

$ICCM stop dilute fck stock !bad managment

0 · Reply

thechad369 Feb. 6 at 3:13 PM

$ICCM putrid volume on 5% unfortunately

0 · Reply

grandpa_dirt Feb. 5 at 3:54 PM

$ICCM Unless they can quadruple their quarterly sales I don't see how they can make it past May without further dilution. Is there any way to know how many ATM warrants are still out?

1 · Reply

SuperBusa Feb. 3 at 6:58 PM

$ICCM

0 · Reply

noonknight Feb. 2 at 12:59 AM

$ICCM Based on the most recent financial data as of early 2026, IceCure Medical (ICCM) is estimated to have approximately 6 to 8 months of cash runway remaining before it will likely need additional financing.Financial Snapshot (Preliminary FY 2025)According to the CEO's January 2026 shareholder letter and the Q3 2025 earnings report:Cash on Hand: Approximately $8.9 million (as of December 31, 2025).Net Loss: The company reported a net loss of approximately $10.8 million for the first nine months of 2025 (roughly $3.6 million per quarter).Recent Funding: ICCM successfully raised capital in late 2025 via a $10 million rights offering and an "at-the-market" (ATM) facility, which bolstered the cash position following the FDA marketing authorization for breast cancer treatment in October 2025.Runway AnalysisGiven the current burn rate and strategic objectives, here is how the runway looks:MetricEstimateEstimated Quarterly Burn~$3.5M – $3.8MCURRENT Cash (Dec 31, 2025)$8.9M

1 · Reply

GJ_Rockabilt Jan. 30 at 2:23 PM

$ICCM This Stock drives me crazy. I've been in and out. I'm Out, now. Today is last day to sign up for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

Lyn30 Jan. 29 at 6:29 PM

$ICCM Only stock I regret putting money as well as disappointed. One account avg 1.01, three account .64. Point is here just concerned if they drag it to .30. The way most Israeli stocks do. Then do RS. I thought its different as huge potential. But they ducked me. If they do have to lose most investment here . I can easily avg down cause I have big portfolio but won’t cause it’s about calculation .

1 · Reply

prismmarketview Jan. 28 at 9:11 PM

$ICCM IceCure Medical received FDA De Novo marketing authorization for its ProSense System to treat patients with early-stage, low-risk breast cancer. This milestone allows for a cryoablation alternative to surgery for certain breast cancer patients in the U.S. https://prismmarketview.com/companies/icecure-medical-ltd/

0 · Reply

SuperBusa Jan. 28 at 2:47 PM

$ICCM

0 · Reply

Joe_088 Jan. 28 at 1:48 PM

$ICCM IceCure's U.S. commercial team continues to see accelerating interest in ProSense®. During recent months, systems were sold and installed at new locations across North America, including at one of the most highly regarded medical institutions in the U.S., reflecting growing clinical interest following the FDA's marketing authorization

0 · Reply

Planetpaprika Jan. 28 at 1:36 PM

$ICCM https://ir.icecure-medical.com/news-events/press-releases/detail/204/icecure-celebrates-american-society-of-breast-surgeons-asbrs-proposed-breast-cancer-treatment-guidelines-which-include-cryoablation-for-low-risk-breast-cancer

0 · Reply

Lyn30 Jan. 28 at 4:18 AM

$ICCM I never sell any of my stock until it reach target . This one I should have sold . Minimum 4 times I had decent profit . But I didn’t sell. This is my last israeliii stock , after that I will only shart.its very hard to make money from Israeliii stocks, that’s why normally I don’t touch. This one accidentally touched due to potential. Then I rewind the button , all israeliii stock looks like same , they have huge potential but stock do same way imo. Once in a while they run big , if anyone catch that then can make huge. Otherwise sitting there seeing small bump here and there imo .

1 · Reply

patcoin Jan. 26 at 8:22 PM

$ICCM high risk high reward. great summary: https://everyticker.com/quote/ICCM/analysis/regulatory-monopoly-meets-commercial-execution-challenge-at-icecure-medical-nasdaq-iccm taking a small position now looking to average down over the coming months if needed. GLHF

0 · Reply

Market Cap	40.61M
Revenue (ttm)	3.29M
Net Income (ttm)	-15.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-465.65%
Debt to Equity Ratio	0.00

Volume	102,800
Avg Vol	313,020
Day's Range	N/A - N/A
Shares Out	68.70M
Stochastic %K	51%
Beta	0.29
Analysts	Strong Sell
Price Target	$3.05